In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19.
Carolina Q SacramentoNatalia Fintelman-RodriguesJairo R TemerozoAline de Paula Dias Da SilvaSuelen da Silva Gomes DiasCarine Dos Santos da SilvaAndré C FerreiraMayara MattosCamila R R PãoCaroline S de FreitasVinicius Cardoso SoaresLucas Villas Bôas HoelzTácio Vinício Amorim FernandesFrederico Silva Castelo BrancoMônica Macedo BastosNúbia BoechatFelipe B SaraivaMarcelo Alves FerreiraSteffen JockuschXuanting WangChuanjuan TaoMinchen ChienWei XieDinshaw PatelAitor GarziaThomas TuschlJames J RussoRajith K R RajoliCarolina S G PedrosaGabriela VitóriaLetícia R Q SouzaLivia Goto-SilvaMarilia Zaluar GuimarãesStevens K RehenAndrew OwenFernando A BozzaDumith Chequer Bou-HabibJingyue JuPatrícia T BozzaThiago Moreno L SouzaPublished in: The Journal of antimicrobial chemotherapy (2021)
Daclatasvir, alone or in combination with sofosbuvir, at higher doses than used against HCV, may be further fostered as an anti-COVID-19 therapy.